Logo

PROF

Profound Medical Corp.

PROF

Profound Medical Corp. • NASDAQ
$6.60 ▲ 2.17% (+0.14)
Market Cap $199.28 M
52w High $8.75
52w Low $3.76
Dividend Yield 0%
P/E -5
Volume 84.51K
Outstanding Shares 30.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.23M ▲ $12.702M ▼ $-7.889M ▲ -150.822% ▲ $0.26 ▲ $-7.624M ▲
Q2-2025 $2.211M ▼ $15.424M ▲ $-15.695M ▼ -709.86% ▼ $-0.52 ▼ $-13.665M ▼
Q1-2025 $2.621M ▼ $13.019M ▼ $-10.724M ▼ -409.157% ▼ $-0.36 ▼ $-11.003M ▲
Q4-2024 $5.327M ▲ $86.102M ▲ $-7.669M ▲ -143.968% ▲ $-0.19 ▲ $-12.055M ▼
Q3-2024 $3.83M $-9.712M $-12.663M -330.65% $-0.38 $-11.926M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $24.826M ▼ $42.305M ▼ $10.162M ▼ $32.143M ▼
Q2-2025 $35.195M ▼ $49.668M ▼ $10.409M ▲ $39.259M ▼
Q1-2025 $46.433M ▼ $60.864M ▼ $10.074M ▲ $50.79M ▼
Q4-2024 $54.912M ▲ $70.234M ▲ $9.812M ▼ $60.422M ▲
Q3-2024 $27.123M $42.235M $11.171M $31.064M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.889M ▲ $-9.48M ▲ $0 $2.268K ▼ $-10.472M ▲ $-9.48M ▲
Q2-2025 $-15.954M ▼ $-14.069M ▼ $0 $5.467K ▲ $-11.162M ▼ $-14.069M ▼
Q1-2025 $-10.724M ▼ $-8.283M ▼ $0 $-290K ▼ $-8.479M ▼ $-8.283M ▼
Q4-2024 $-5.334M ▲ $-5.642M ▲ $0 $35.653M ▲ $27.789M ▲ $-5.642M ▲
Q3-2024 $-9.365M $-6.826M $0 $-592K $-6.956M $-6.826M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Capital Equipment
Capital Equipment
 $0 ▲$0 ▲$0 ▲
Recurring NonCapital
Recurring NonCapital
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Profound Medical is still in an early commercial stage, with very small revenue and no clear ramp-up yet. Gross profit only recently turned modestly positive, and operating results have been consistently negative for several years. Losses have been fairly steady rather than widening dramatically, but the company is clearly not close to break-even. Earnings per share remain meaningfully negative, although there has been a slight directional improvement most recently. Overall, the income statement reflects a business focused on building and commercializing its technology rather than generating scale revenue at this point.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and dominated by cash and other short-term assets, with only a small amount of debt. Equity has shrunk over time as losses accumulated, but there was a noticeable improvement in cash and total assets in the latest year, likely from new financing. Leverage remains low, which reduces financial risk, but the company’s net worth depends heavily on continued investor support until the business becomes self-funding. Asset intensity is low, fitting a technology-driven, rather than manufacturing-heavy, model.

Cash Flow

Cash Flow Profound Medical has been using cash rather than generating it for several years. Operating cash flow is consistently negative, and because capital spending is minimal, free cash flow is essentially the same as operating cash flow. This means the cash burn is mostly tied to operating expenses such as R&D, clinical work, and commercialization efforts. The company’s runway is determined by its cash balance and access to new capital, so ongoing funding is a central consideration while revenues remain small.

Competitive Edge

Competitive Edge The company’s technology sits in a promising niche of minimally invasive, image-guided therapies. Its TULSA-PRO and Sonalleve platforms are differentiated by real-time MRI guidance, closed-loop temperature control, and a strong emphasis on preserving patient quality of life. Regulatory clearances in major markets, a growing base of clinical data, and partnerships with large imaging companies give it a tangible competitive edge and barriers to entry. At the same time, it must contend with entrenched standard-of-care treatments, reimbursement hurdles, and competition from larger device companies that have broader commercial infrastructures. Adoption will hinge on continued proof of superior outcomes, cost-effectiveness, and physician training.

Innovation and R&D

Innovation and R&D Profound Medical is clearly R&D-heavy, with its spending focused on refining TULSA-PRO, expanding indications, and broadening the use of Sonalleve. The company is pushing into areas like AI-assisted planning, additional prostate and benign disease indications, and new tumor and pain-management applications. It is also generating long-term clinical data to strengthen its case with physicians, regulators, and payers, and pursuing geographic expansion. This innovation strategy offers significant upside potential but also requires sustained investment and careful execution, especially given the company’s current loss-making profile.

Summary

Profound Medical is a highly innovative, early-stage medical device company with a compelling technology story but still nascent commercial traction. The financials show a typical pattern for a growth-stage medtech: small revenue, recurring operating losses, negative cash flow, and reliance on external financing, albeit with limited debt. Its competitive position is supported by distinctive technology, regulatory approvals, and strong partners, yet real-world adoption and reimbursement are still key uncertainties. Future value creation depends on converting its strong innovation pipeline and clinical data into meaningful, repeatable revenue while managing cash burn and execution risk.

NEWS

November 28, 2025 · 7:45 AM UTC

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

Read more

November 18, 2025 · 4:15 PM UTC

Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

Read more

November 13, 2025 · 4:05 PM UTC

Profound Medical Reports Strong Third Quarter 2025 Financial Results

Read more

November 12, 2025 · 8:30 AM UTC

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

Read more

November 11, 2025 · 4:15 PM UTC

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

Read more